You are here: Home » 0 » » Archives for 0st

Emirate Lithium Commences Pre-Feasibility Studies of its Iwajowa and Kaima Lithium Projects

LAGOS, Nigeria, Sept. 07, 2022 (GLOBE NEWSWIRE) — Emirate Lithium & Geominerals Limited ("Emirate Lithium" or the "Company"), a subsidiary of Emirate Group focused on the exploration, mining, trading and exporting of solid mineral ores, including lithium spodumene, tin, columbite, zircon sand (brown), monazite and tantalite to Europe and Asia, announced today that it has signed contracts with AGVision Mining Limited ("AG Vision") to carry out pre–feasibility studies for its licensed Iwajowa and Kaima lithium projects located within the known pegmatite belt in southwestern and north–central Nigeria. The Nigerian Geological Survey Agency, the Federal Nigerian agency charged with developing geo–science data, is currently carrying out several early–stage exploration programs within Nigeria's pegmatite belt.

AGVision was founded by a group of Nigerian engineering, procurement, and construction managers and a world–leading Australian geological, geophysical, and geospatial company "" International Geoscience Pty Limited. International Geoscience is led by Dr. Warwick Crowe, a globally recognized structural geologist and one of the world's foremost experts on Nigeria's economic geology. AGVision delivers the Australian Joint Ore Reserves Committee (JORC) reporting standards in its various exploratory activities and reporting.

"This is an important milestone for Emirate Lithium, setting the stage for the next phase of our corporate evolution," said Lanre Afebuameh, Founder and CEO of Emirate Lithium. "While the pre–feasibility studies are conducted over the next several months, our team will continue to focus on our current surface mining operations, which have yielded average annual export volume of $4.5 million and approximately 6% spodumene concentrations since launching in 2020."

While Emirate Lithium's exports have primarily targeted Asia, the Company anticipates increased demand for its high–grade ore from European electric vehicle and battery manufacturers.

About Emirate Lithium

Emirate Lithium was incorporated in 2017 and commenced operations in 2018 as a mining, minerals, processing, and export company. The Company commenced open pit mining (surface mining) operations working with artisanal and small–scale operators in 2020 to establish lithium ore–grade quantities and build customer demand. Emirate Lithium currently has 27 minerals exploration licenses acquired from the Nigerian Minerals Cadatral Office ("MCO"). Six of the 27 licenses are for lithium, making the Company a major holder of lithium assets in Sub–Sahara Africa, with Emirate Lithium poised to become the largest holder of lithium assets in the continent.

Cautionary Note Regarding Forward–Looking Statements
This news release includes certain “forward–looking statements” for the purpose of providing information about management's current expectations and plans relating to the future. Forward–looking statements are based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward–looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward–looking statements. Emirate Lithium disclaims any intention or obligation to update or revise any forward–looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact

Dave Gentry, CEO
RedChip Companies, Inc.
1–800–Red–Chip (733–2441)
emirate@redchip.com


Zenas BioPharma Appoints Simon Lowry, M.D. as Chief Medical Officer

WALTHAM, Mass. and SHANGHAI, China, Sept. 07, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune–based therapies for patients in need around the world, today announced the appointment of Simon Lowry, M.D., as the company's Chief Medical Officer. Dr. Lowry brings over 20 years of broad clinical expertise in the design and execution of early to late–stage clinical programs to Zenas, where he will lead the company's global clinical, medical affairs, and pharmacovigilance functions.

"We are delighted to welcome Dr. Lowry to Zenas at this pivotal time for the company as we commence two phase three registration trials for our lead product candidate, obexelimab, in the fourth quarter of this year and initiate first–in–human clinical trials for multiple pipeline programs," said Hua Mu, M.D., Ph. D, Chief Executive Officer at Zenas. "Dr. Lowry's proven leadership, broad clinical development background, and extensive global clinical trial experience will further strengthen our ability to execute on our mission to transform the lives of patients with unmet medical needs by bringing best–in–class immune–based therapies to patients."

Dr. Simon Lowry added, "There are many patients with autoimmune and rare diseases in need of effective new treatment options. The deeply experienced and talented Zenas team has made impressive progress advancing the company's pipeline in a very short period of time, and I look forward to leading the ongoing advancement of Zenas' clinical programs through commercialization while further expanding the company's pipeline of innovative programs."

Dr. Lowry is a medical doctor with 20 years of experience at large and emerging pharmaceutical and biotechnology companies directing successful development programs, leading clinical and medical affairs teams, and interacting with regulatory agencies across multiple areas of medicine, including rheumatology, immunology, and ophthalmology. Prior to joining Zenas, Dr. Lowry was Chief Medical Officer at Kinevant Science, a clinical–stage biopharmaceutical company focused on treating rare inflammatory and autoimmune diseases. Dr. Lowry was previously Head of Immunology R&D at Roivant Sciences, leading all development stage immunology assets into clinical development, and served as a key member of the leadership team. He also served as Chief Medical Officer at Sun Pharma North America, where he was responsible for four branded therapeutic areas (Immunology & Dermatology, Ophthalmology, Neurology and Oncology), and led all aspects of development and medical functions (including clinical development, medical information, field medical, HEOR, publications / medical communications, and operations). Early in his career, he worked at Novartis, where he served as Vice President, Global Medical Affairs Franchise Head, Immunology & Dermatology, and Pfizer, where he served in roles of increasing responsibility, including as Vice President, Oncology Medical Affairs Group Leader.

Prior to his pharmaceutical/ biotechnology career, Dr. Lowry practiced internal medicine at various institutions in the UK and Australia. He received his BA from Trinity Hall, Cambridge University, UK and his MB BChir medical degree from Cambridge University School of Clinical Medicine.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune–based therapies for patients around the world. With clinical development and operations in the US and China, Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com